Zhang YY [56] (2020)
|
Single-arm study
|
January 2013-Septemper 2018
|
35
|
43 (40–54)
|
23/11
|
SAA/VSAA (19/16)
|
BU + CY + ATG
|
CsA + MMF + MTX
|
NA
|
13 (9–21)
|
17 (10–102)
|
NA
|
6
|
Ma YR [55] (2020)
|
Single-arm study
|
NA
|
199
|
NA
|
106/93
|
NA
|
BU + CY + ATG
|
CsA + MMF + MTX
|
NA
|
NA
|
NA
|
NA
|
6
|
Liu LM [54] (2020)
|
Single-arm study
|
Septemper 2010-Septemper 2018
|
16
|
32 (8–55)
|
9/7
|
NA
|
ATG + rituximab
|
NA
|
NA
|
11 (9–20)
|
21 (13–112)
|
NA
|
6
|
Yang SW [22] (2019)
|
Single-arm study
|
NA
|
32
|
NA
|
21/11
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
6
|
Xu LP5 [53] (2019)
|
Single-arm study
|
2006–2018
|
392
|
NA
|
223/167
|
NA
|
BU + CY + ATG
|
CsA + MMF + MTX
|
NA
|
12 (9–31)
|
14 (5–180)
|
NA
|
6
|
Hyery Kim [52] (2019)
|
Single-arm study
|
2008–2017
|
32
|
12.7 (1.4–21.7)
|
22/10
|
SAA/VSAA (20/12)
|
FLU, CY, ATG ± TBI
|
CsA + MMF
|
5.2 (1.2–106.8)
|
10 (9–30)
|
15.5 (13–60)
|
NA
|
5
|
Lu Y [51] (2018)
|
Single-arm study
|
Septemper 2012-Septemper 2016
|
41
|
13 (4–42)
|
25/16
|
SAA/VSAA(28/13)
|
FLU, CY, ATG
|
CsA + MMF + MTX
|
25 (6–45)
|
14 (10–21)
|
13 (3–56)
|
NA
|
6
|
Sung-Eun Lee [24] (2018)
|
Single-arm study
|
June 2012-December 2016
|
34
|
31.5 (17–59)
|
20/14
|
SAA/VSAA (11/23)
|
ATG + TBI + FLU
|
CsA + MTX
|
NA
|
12 (11–12)
|
14 (5–86)
|
NA
|
5
|
Cheng YF [50] (2018)
|
Single-arm study
|
December 2007-Septemper 2016
|
28
|
NA
|
NA
|
NA
|
NA
|
NA
|
2.75 (1–8)
|
12 (10–21)
|
NA
|
NA
|
6
|
Cao LQ [49] (2018)
|
Single-arm study
|
January 2006-December 2016
|
131
|
16 (2–45)
|
70/61
|
NA
|
NA
|
NA
|
NA
|
12 (10–31)
|
16 (7–276)
|
NA
|
5
|
Zhang P [48] (2017)
|
Single-arm study
|
June 2014-December 2015
|
8
|
14 (5–26)
|
5/3
|
NA
|
FLU, CY, ALG/TBI
|
CsA + MMF + MTX
|
NA
|
14.8 (11–20)
|
15.0 (11–21)
|
NA
|
6
|
Zhang Y [47] (2017)
|
Single-arm study
|
June 2010-December 2014
|
18
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
16 (12–26)
|
20 (17–35)
|
NA
|
5
|
Pei XY [46] (2017)
|
Single-arm study
|
January 2008-December 2015
|
81
|
14 (3–45)
|
50/31
|
SAA/VSAA (63/18)
|
NA
|
NA
|
NA
|
12 (10–22)
|
15 (7–150)
|
NA
|
6
|
Sarita Rani Jaiswal [45] (2017)
|
Single-arm study
|
January 2015-May 2016
|
20
|
NA
|
NA
|
NA
|
FLU, CY, ATG, melphalan
|
PTCy + sirolimus + CsA + MMF (abatacept)
|
NA
|
NA
|
NA
|
NA
|
5
|
Amy E. DeZern [44](2017)
|
Single-arm study
|
July 2011-August 2016
|
13
|
33 (11–69)
|
9/5
|
NA
|
FLU, CY, ATG ± TBI
|
PTCy+MMF + FK506
|
NA
|
19 (16–27)
|
28 (22–108)
|
NA
|
5
|
Zhu H [43] (2016)
|
Single-arm study
|
July 2002-November 2013
|
38
|
NA
|
12/24
|
SAA/VSAA (8/28)
|
FLU, CY, ATG ± TBI/BU
|
CsA + methotrexate (MTX) (n = 12) CsA + MTX + mycophenolate mofetil (MMF) (n = 22) MTX + tacrolimus (n = 4)
|
NA
|
NA
|
NA
|
NA
|
6
|
Liu L [42] (2016)
|
Single-arm study
|
July 2005-December 2013
|
26
|
26 (10–54)
|
15/11
|
SAA/VSAA/(16/6)
|
NA
|
NA
|
NA
|
12 (6–28)
|
19 (12–330)
|
NA
|
5
|
Ho Joon Im [41] (2015)
|
Single-arm study
|
NA
|
21
|
14 (3–21)
|
NA
|
NA
|
FLU, CY, ATG ± TBI
|
NA
|
NA
|
NA
|
NA
|
NA
|
6
|
Esteves I [25] (2015)
|
Single-arm study
|
July 2010-August 2014
|
16
|
17 (5–39)
|
11/5
|
NA
|
CY + FLU+ TBI, FLU + ATG (2)
|
MMF, CsA, Cy
|
NA
|
19 (16–29)
|
21 (20–29)
|
NA
|
6
|
Gao L [40] (2014)
|
Single-arm study
|
June 2007-December 2010
|
26
|
25.4 (18–41)
|
NA
|
SAA/VSAA (16/10)
|
FLU, CY, ATG
|
CsA + MMF + MTX + ATG
|
NA
|
13 (11–19)
|
13 (10–21)
|
NA
|
5
|
Jennifer Clay [39] (2014)
|
Single-arm study
|
NA
|
8
|
NA
|
NA
|
NA
|
CY + FLU + TBI
|
MMF + FLU + PTCY
|
NA
|
18.5 (16–23)
|
26 (21–27)
|
NA
|
5
|